Collagen type V oral solution

Drug Profile

Collagen type V oral solution

Alternative Names: IW001

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmuneWorks
  • Developer ImmuneWorks; Lung Biotechnology
  • Class Collagens
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Idiopathic pulmonary fibrosis; Lung transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-transplant-rejection in USA (PO, Liquid)
  • 03 Apr 2012 ImmuneWorks & Lung Rx complete enrolment in their phase I trial for Idiopathic pulmonary fibrosis in USA (NCT01199887)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top